Individual patient data meta-analysis of docetaxel administered once every 3 weeks compared with once every week second-line treatment of advanced non-small-cell lung cancer

Massimo Di Maio, Francesco Perrone, Paolo Chiodini, Ciro Gallo, Carlos Camps, Wolfgang Schuette, Elisabeth Quoix, Chun Ming Tsai, Cesare Gridelli

Research output: Contribution to journalArticle

Abstract

Purpose: Although several randomized trials have been performed comparing weekly docetaxel (wD) with standard docetaxel once every 3 weeks (3wD) as second-line treatment of advanced non-small-cell lung cancer (NSCLC), no single trial had sufficient power to detect clinically relevant differences in survival. Methods: We performed a meta-analysis based on individual patient data from all identified randomized trials comparing wD with 3wD as second-line treatment of advanced NSCLC. Baseline characteristics, treatment assigned, and outcome data were collected for each patient. The primary end point was overall survival. All statistical analyses were stratified by trial. Results: Five eligible trials were identified for a total of 865 patients: 433 patients had been assigned to 3wD, and 432 patients had been assigned to wD. Median age was 62 years (range, 26 to 80 years). Performance status was 0 in 23%, 1 in 58%, and 2 in 16% of patients; 91 % of the patients had received previous platinum, and 14% had received previous paclitaxel. With 733 deaths recorded (85%), median survival was 27.4 weeks for patients treated with 3wD, and 26.1 weeks for patients treated with wD (P = .24, log-rank test). There was no significant heterogeneity among the five trials. No relevant differential effect was detected in subgroup analyses. Significantly less severe and febrile neutropenia was reported with wD (P <.00001 for both), whereas no significant differences were observed for anemia, thrombocytopenia, and nonhematologic toxicity. Conclusion: wD shows similar efficacy compared with 3wD, and represents an alternative for second-line treatment of advanced NSCLC.

Original languageEnglish
Pages (from-to)1377-1382
Number of pages6
JournalJournal of Clinical Oncology
Volume25
Issue number11
DOIs
Publication statusPublished - Apr 10 2007

Fingerprint

docetaxel
Non-Small Cell Lung Carcinoma
Meta-Analysis
Therapeutics
Survival
Febrile Neutropenia
Paclitaxel
Platinum

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Individual patient data meta-analysis of docetaxel administered once every 3 weeks compared with once every week second-line treatment of advanced non-small-cell lung cancer. / Di Maio, Massimo; Perrone, Francesco; Chiodini, Paolo; Gallo, Ciro; Camps, Carlos; Schuette, Wolfgang; Quoix, Elisabeth; Tsai, Chun Ming; Gridelli, Cesare.

In: Journal of Clinical Oncology, Vol. 25, No. 11, 10.04.2007, p. 1377-1382.

Research output: Contribution to journalArticle

Di Maio, Massimo ; Perrone, Francesco ; Chiodini, Paolo ; Gallo, Ciro ; Camps, Carlos ; Schuette, Wolfgang ; Quoix, Elisabeth ; Tsai, Chun Ming ; Gridelli, Cesare. / Individual patient data meta-analysis of docetaxel administered once every 3 weeks compared with once every week second-line treatment of advanced non-small-cell lung cancer. In: Journal of Clinical Oncology. 2007 ; Vol. 25, No. 11. pp. 1377-1382.
@article{09ad791b1fa54e10a4f3f882c8f83680,
title = "Individual patient data meta-analysis of docetaxel administered once every 3 weeks compared with once every week second-line treatment of advanced non-small-cell lung cancer",
abstract = "Purpose: Although several randomized trials have been performed comparing weekly docetaxel (wD) with standard docetaxel once every 3 weeks (3wD) as second-line treatment of advanced non-small-cell lung cancer (NSCLC), no single trial had sufficient power to detect clinically relevant differences in survival. Methods: We performed a meta-analysis based on individual patient data from all identified randomized trials comparing wD with 3wD as second-line treatment of advanced NSCLC. Baseline characteristics, treatment assigned, and outcome data were collected for each patient. The primary end point was overall survival. All statistical analyses were stratified by trial. Results: Five eligible trials were identified for a total of 865 patients: 433 patients had been assigned to 3wD, and 432 patients had been assigned to wD. Median age was 62 years (range, 26 to 80 years). Performance status was 0 in 23{\%}, 1 in 58{\%}, and 2 in 16{\%} of patients; 91 {\%} of the patients had received previous platinum, and 14{\%} had received previous paclitaxel. With 733 deaths recorded (85{\%}), median survival was 27.4 weeks for patients treated with 3wD, and 26.1 weeks for patients treated with wD (P = .24, log-rank test). There was no significant heterogeneity among the five trials. No relevant differential effect was detected in subgroup analyses. Significantly less severe and febrile neutropenia was reported with wD (P <.00001 for both), whereas no significant differences were observed for anemia, thrombocytopenia, and nonhematologic toxicity. Conclusion: wD shows similar efficacy compared with 3wD, and represents an alternative for second-line treatment of advanced NSCLC.",
author = "{Di Maio}, Massimo and Francesco Perrone and Paolo Chiodini and Ciro Gallo and Carlos Camps and Wolfgang Schuette and Elisabeth Quoix and Tsai, {Chun Ming} and Cesare Gridelli",
year = "2007",
month = "4",
day = "10",
doi = "10.1200/JCO.2006.09.8251",
language = "English",
volume = "25",
pages = "1377--1382",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "11",

}

TY - JOUR

T1 - Individual patient data meta-analysis of docetaxel administered once every 3 weeks compared with once every week second-line treatment of advanced non-small-cell lung cancer

AU - Di Maio, Massimo

AU - Perrone, Francesco

AU - Chiodini, Paolo

AU - Gallo, Ciro

AU - Camps, Carlos

AU - Schuette, Wolfgang

AU - Quoix, Elisabeth

AU - Tsai, Chun Ming

AU - Gridelli, Cesare

PY - 2007/4/10

Y1 - 2007/4/10

N2 - Purpose: Although several randomized trials have been performed comparing weekly docetaxel (wD) with standard docetaxel once every 3 weeks (3wD) as second-line treatment of advanced non-small-cell lung cancer (NSCLC), no single trial had sufficient power to detect clinically relevant differences in survival. Methods: We performed a meta-analysis based on individual patient data from all identified randomized trials comparing wD with 3wD as second-line treatment of advanced NSCLC. Baseline characteristics, treatment assigned, and outcome data were collected for each patient. The primary end point was overall survival. All statistical analyses were stratified by trial. Results: Five eligible trials were identified for a total of 865 patients: 433 patients had been assigned to 3wD, and 432 patients had been assigned to wD. Median age was 62 years (range, 26 to 80 years). Performance status was 0 in 23%, 1 in 58%, and 2 in 16% of patients; 91 % of the patients had received previous platinum, and 14% had received previous paclitaxel. With 733 deaths recorded (85%), median survival was 27.4 weeks for patients treated with 3wD, and 26.1 weeks for patients treated with wD (P = .24, log-rank test). There was no significant heterogeneity among the five trials. No relevant differential effect was detected in subgroup analyses. Significantly less severe and febrile neutropenia was reported with wD (P <.00001 for both), whereas no significant differences were observed for anemia, thrombocytopenia, and nonhematologic toxicity. Conclusion: wD shows similar efficacy compared with 3wD, and represents an alternative for second-line treatment of advanced NSCLC.

AB - Purpose: Although several randomized trials have been performed comparing weekly docetaxel (wD) with standard docetaxel once every 3 weeks (3wD) as second-line treatment of advanced non-small-cell lung cancer (NSCLC), no single trial had sufficient power to detect clinically relevant differences in survival. Methods: We performed a meta-analysis based on individual patient data from all identified randomized trials comparing wD with 3wD as second-line treatment of advanced NSCLC. Baseline characteristics, treatment assigned, and outcome data were collected for each patient. The primary end point was overall survival. All statistical analyses were stratified by trial. Results: Five eligible trials were identified for a total of 865 patients: 433 patients had been assigned to 3wD, and 432 patients had been assigned to wD. Median age was 62 years (range, 26 to 80 years). Performance status was 0 in 23%, 1 in 58%, and 2 in 16% of patients; 91 % of the patients had received previous platinum, and 14% had received previous paclitaxel. With 733 deaths recorded (85%), median survival was 27.4 weeks for patients treated with 3wD, and 26.1 weeks for patients treated with wD (P = .24, log-rank test). There was no significant heterogeneity among the five trials. No relevant differential effect was detected in subgroup analyses. Significantly less severe and febrile neutropenia was reported with wD (P <.00001 for both), whereas no significant differences were observed for anemia, thrombocytopenia, and nonhematologic toxicity. Conclusion: wD shows similar efficacy compared with 3wD, and represents an alternative for second-line treatment of advanced NSCLC.

UR - http://www.scopus.com/inward/record.url?scp=34248159348&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34248159348&partnerID=8YFLogxK

U2 - 10.1200/JCO.2006.09.8251

DO - 10.1200/JCO.2006.09.8251

M3 - Article

C2 - 17416857

AN - SCOPUS:34248159348

VL - 25

SP - 1377

EP - 1382

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 11

ER -